Hubertus von Baumbach, Boehringer Ingelheim's chairman of the board of managing directors, at its annual press conference on April 16, 2024 (Arne Dedert/picture-alliance/dpa/AP Images)
Boehringer Ingelheim touts 10-year plan as it eyes overtaking Bayer as Germany’s largest pharma
Boehringer Ingelheim put the spotlight on a pipeline ripe with milestones over the next decade during its full-year 2023 call with the press.
Driven in part by the blockbuster success of its diabetes and heart drug Jardiance, Boehringer may have surpassed Bayer to become the biggest German drugmaker, according to media comments on the call. Below, Endpoints News highlights eight key takeaways from the media event:
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
